

A Series in Integrative Medicine

# **Clinical Practice Guidelines on the Use of Integrative Therapies as Supportive Care in Patients Treated for Breast Cancer**

**Heather Greenlee, ND, PhD**

Assistant Professor Department of Epidemiology  
Mailman School of Public Health – Columbia University

Immediate Past President – Society for Integrative Oncology

**November 20, 2014**

Jointly sponsored by Vanderbilt University School of Medicine  
Department of Medicine, Division of General Internal Medicine and Public Health  
and the  
Consortium of Academic Health Centers for Integrative Medicine (CAHCIM)

# AMA Objectives

After participating in this CME activity, participants should be able to describe and discuss how to:

- Engage their patients with a holistic and collaborative approach to healing
- Refer patients with chronic illness and chronic pain to appropriate integrative modalities for care
- Use basic coaching and motivational interviewing skills to engage healthy behavior change

# APA Objectives

After participating in this CE activity, participants should be able to:

- To characterize unmet needs in the management of symptom complexes in patients treated for breast cancer
- To enumerate and grade the benefits and harms of integrative approaches for defined symptoms for breast cancer treatment
- To compose a framework for evidence-based management strategies for patients being treated for breast cancer

# Target Audience

Physicians, Psychologists and other health professionals from the United States and Canada who are members of the Consortium of Academic Health Centers for Integrative Medicine.

# Instructional Level

Intermediate

# Disclosures

It is the policy of Vanderbilt University School of Medicine and the Consortium of Academic Health Centers for Integrative Medicine to require the disclosure of financial relationships from individuals in a position to control the content of a CME activity; to identify and resolve conflicts of interest related to those relationship; and to make disclosure information available to the audience prior to the CME activity. Presenters are required to disclose discussion of unlabeled/unapproved uses of drugs or devices during their presentations.

Course Director: **Gurjeet Birdee, MD**, Assistant Professor in Internal Medicine and Pediatrics at Vanderbilt University School of Medicine

Planner: **Tobi Fishel, PhD**, Associate Professor in the Departments of Psychiatry, Psychology and Pediatrics at Vanderbilt School of Medicine

Planner: **Jeff Feldman, PhD**, Assistant Professor of Neurology at Wake Forest Medical Center

Planner: **Amy Locke, MD**, Assistant Professor in Department of Family Medicine at University of Michigan Medical School

Speaker: **Heather Greenlee, ND, PhD**, Assistant Professor Department of Epidemiology at Mailman School of Public Health, Columbia University; Immediate Past President, Society for Integrative Oncology

All course directors, planners and speakers have no financial relationships to disclose.

This educational activity received no commercial support.

# CME Credit

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of Vanderbilt University School of Medicine and the Consortium of Academic Health Centers for Integrative Medicine. Vanderbilt University School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Vanderbilt University School of Medicine designates this live activity for a maximum of *1.0 AMA PRA Category 1 Credit(s)*™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

# CE Credit



Vanderbilt University School of Medicine is approved by the American Psychological Association to sponsor continuing education for psychologists. Vanderbilt University School of Medicine maintains responsibility for this program and its content. Vanderbilt University School of Medicine designates this educational activity for **1.0** CE credits toward the continuing education of psychologists.

No partial credit may be awarded.

# Credit Requirements

- This CME/CE activity consists of a simultaneous Power Point presentation and conference call followed by an evaluation, and will require approximately one hour of your time.
- To obtain CME/CE credit for your participation in this activity, you must:
  - View the entire presentation.
  - Submit your contact information to [info@imconsortium.org](mailto:info@imconsortium.org).
  - Complete and submit an evaluation form by Friday, November 28<sup>th</sup>.
- After completing these tasks, your credit will be available in 3 weeks.
- Once your CME certificate is available you will receive an email notification from [CME@Vanderbilt.edu](mailto:CME@Vanderbilt.edu) with log-in information to the CME Website. By following the email instructions, you may retrieve your certification.
- If you do not receive an email notification, please check your spam/junk folder before contacting CME at Vanderbilt or [infor@imconsortium.org](mailto:infor@imconsortium.org) .
- Personal information is used for issuing a CME or CE credit certificate and storing that credit in the Vanderbilt OCPD database.

If you have questions or need additional information contact [info@imconsortium.org](mailto:info@imconsortium.org)

# Americans with Disabilities Act

It is the policy of Vanderbilt University School of Medicine and the Consortium of Academic Health Centers for Integrative Medicine not to discriminate against any person on the basis of disabilities.

If you feel you need services or auxiliary aids mentioned in this act in order to fully participate in this continuing education activity, please speak with a course director or planner.

# Bibliographic Sources

- Greenlee H, Balneaves LB, Carlson LE, Cohen M, Deng G, Hershman D, Mumber M, Perlmutter J, Seely D, Sen A, Zick SM, Tripathy D. Clinical practice guidelines on the use of integrative therapies as supportive care in patients treated for breast cancer. *J Natl Cancer Inst Monogr.* 2014; 50: 346-358.

# Clinical Practice Guidelines on the Use of Integrative Therapies as Supportive Care in Patients Treated for Breast Cancer

**Heather Greenlee**<sup>1</sup>, Lynda Balneaves<sup>2,3</sup>, Linda Carlson<sup>4</sup>,  
Misha Cohen<sup>5,6</sup>, Gary Deng<sup>7</sup>, Dawn Hershman<sup>1</sup>,  
Matthew Mumber<sup>8</sup>, Jane Perlmutter<sup>9</sup>, Dugald Seely<sup>10,11</sup>,  
Ananda Sen<sup>12</sup>, Suzanna Zick<sup>12</sup>, Debu Tripathy<sup>13</sup>

<sup>1</sup>Columbia University, <sup>2</sup>University of British Columbia, <sup>3</sup>University of Toronto,  
<sup>4</sup>University of Calgary, <sup>5</sup>University of California San Francisco, <sup>6</sup>Chicken Soup  
Chinese Medicine, <sup>7</sup>Memorial Sloan Kettering Cancer Center, <sup>8</sup>Harbin Clinic, <sup>9</sup>Gemini  
Consulting, <sup>10</sup>Ottawa Integrative Cancer Center, <sup>11</sup>Canadian College of Naturopathic  
Medicine, <sup>12</sup>University of Michigan, <sup>13</sup>MD Anderson Cancer Center

Presentation to the Consortium of Academic Health Centers for Integrative Medicine

November 20, 2014

# Previous SIO Clinical Guidelines

## General

- Integrative Oncology Practice Guidelines, *JSIO* 2007
- Evidence-Based Clinical Practice Guidelines for Integrative Oncology: Complementary Therapies and Botanicals, *JSIO* 2009

## Lung Cancer

- Complementary Therapies and Integrative Oncology in Lung Cancer: ACCP Evidence-Based Clinical Practice Guidelines (2nd Edition), *Chest* 2007
- Complementary Therapies and Integrative Medicine in Lung Cancer: Diagnosis and Management of Lung Cancer: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (3rd edition), *Chest* 2013



# National Guideline Clearinghouse

[Help](#) | [Videos](#) | [RSS](#) |  [Subscribe to weekly e-mail](#) | [Site map](#) | [Contact us](#) | [For web developers](#)

T- T+

Home

Guidelines

Expert Commentaries

Guideline Syntheses

Guideline Matrix

Guideline Resources

Compare Guidelines

FAQ

Submit Guidelines

About

My NGC

**NGC is a public resource for evidence-based clinical practice guidelines.**

Search the site:

[Search Tips](#) | [Advanced Search](#) | [About Search](#)

► [Show Advanced Search filters](#)

**My Recent Searches:** [integrative oncology](#)

### New This Week

October 20, 2014

#### New/Updated Guideline Summaries

- [AAACE, ACCF, ACP, ACR](#)

[View All](#)

### Announcements

#### Conference News

- The **Guidelines International Network North America (G-I-N NA)** continues to sponsor a monthly webinar series on topics of interest. Information on upcoming webinars is available on the [G-I-N Web site](#).

[More...](#)

### Sign In to My NGC

Save your favorite guideline summaries and organizations, and create custom e-mail alerts.

E-mail:

Password:

Remember Me

[Forgot your password?](#)

**New User?** [Create a free account](#)

### My Recently Viewed Guideline Summaries

- [Guideline on antibiotic prophylaxis for dental patients at risk for infection.](#)



**Technical Assistance Videos**



Find

- [Topic](#)
- [Organizations](#)
- [Guideline Index](#)



Learn

- [AHRQ Evidence Reports](#)
- [Hospital-Acquired Conditions](#)
- [Mobile Device Resources](#)



Compare

- [Guideline Syntheses](#)
- [Compare Guidelines](#)



National Center for Complementary  
and Alternative Medicine (NCCAM)

NIH...Turning Discovery Into Health®

 Search

Follow NCCAM:

[Home](#)
[Health Info](#)
[Research](#)
[Grants & Funding](#)
[Training](#)
[News](#)
[About NCCAM](#)

## Clinical Practice Guidelines

"Clinical practice guidelines are systematically developed statements to assist practitioner and patient decisions about appropriate health care for specific clinical circumstances." (Institute of Medicine, 1990)

Issued by third-party organizations, diagnostic and treatment modalities, and contain recommendations that are based on the published medical literature.

These guidelines are not fixed; they are intended for professionals and providers to use as a guide. In some courses of intervention, they are intended for knowledgeable health care professionals.

### Featured Guidelines

- [Standards for Developing Trustworthy Clinical Practice Guidelines](#) (IOM)
- [Institute of Medicine's Report \*Clinical Practice Guidelines We Can Trust\*](#) (IOM)
- [National Guideline Clearinghouse](#) (AHRQ)

### Allergy and Immunology

- [Allergic Rhinitis and Its Impact on Asthma \(ARIA\) Guidelines: 2010 Revision](#) (*Journal of Allergy and Clinical Immunology*) [171KB PDF]
- [Diagnosis and Management of Food Allergy](#) (*Journal of Allergy and Clinical Immunology*) [165KB PDF]
- [Guidelines for the Diagnosis and Management of Asthma](#) (NHLBI)

### Neurology

- [Alternative Therapies for Parkinson's Disease](#) (*Neurology*) [361KB PDF]

### Oncology

- [Exercise Guidelines for Cancer Survivors](#) (*Med Sci Sports Exerc*)
- [Integrative Oncology in Lung Cancer](#) (*Chest*)
- [Integrative Oncology: Complementary Therapies and Botanicals](#) (*Society for Integrative Oncology*)

### Pain Management

Stay Connected

Via email, RSS, Twitter , or

## TIME TO TALK

DISCUSS use of  
complementary health practices

[nccam.nih.gov/timetotalk](http://nccam.nih.gov/timetotalk)

**“Clinical Practice Guidelines** are statements that include recommendations intended to optimize patient care that are informed by a systematic review of evidence and an assessment of the benefits and harms of alternative care options.”


– 2011, *US Institute of Medicine*

# Why bother with Clinical Practice Guidelines?

- Provide clinicians and patients with a trustworthy tool for managing clinical problems
- Represent the current state of science
- Help an organization increase visibility, credibility and impact in their professional community

# Systematic Reviews and Clinical Practice Guidelines Improve Healthcare Decision Making

Click on any text for more information



# IOM Standards for Developing Trustworthy Clinical Practice Guidelines

1. Establish transparency
2. Manage conflicts of interest (COI)
3. Guideline development group composition
4. Clinical practice guideline-systematic review intersection
5. Establish evidence foundations to rate strength of recommendations
6. Articulate recommendations in a standardized form and phrase so that compliance with the recommendation(s) can be evaluated
7. External reviewers should comprise a full spectrum of relevant stakeholders
8. Update on a regular basis

# Phase I: SIO Guideline Task Force

- Assemble SIO Guideline Task Force (Spring 2013)
  - Gary Deng, MD, PhD, Memorial Sloan Kettering Cancer Center – SIO Past President
  - Heather Greenlee, ND, PhD, Columbia University – SIO President
  - Suzanna Zick, ND, MPH, University of Michigan – SIO President Elect
- Identify topic (Summer 2013)
- Establish process for developing SIO guidelines (Summer/Fall 2013)
  - Identify areas of expertise for representation
  - Identify multidisciplinary Working Group members
  - Develop process to manage Conflicts of Interest
  - Develop timeline

# Complementary & integrative medicine (CIM) use among breast cancer survivors

- 2.8+ million breast cancer survivors in the US
- 48-80% of breast cancer patients use CIM
- Intended uses of CIM after diagnosis include:
  - Prevent & treat side effects of conventional therapies
  - Improve quality of life, functional status and emotional state
  - Increase efficacy of conventional cancer therapies
  - Secondary cancer prevention
  - Meet needs not addressed by conventional therapies
  - Treat comorbidities
  - Health promotion

# Phase II: Guidelines Working Group

## Co-Chairs

- **Heather Greenlee**, ND, PhD, MPH – naturopathic medicine, acupuncture, natural products, epidemiology, clinical trials
- **Debu Tripathy**, MD – breast medical oncology, natural products, clinical trials

## Members

- **Lynda Balneaves**, PhD, RN – nursing, natural products, clinical trials
- **Linda Carlson**, PhD, Rpsych – clinical psychology, mind-body, clinical trials
- **Misha Cohen**, OMD, LAc – acupuncture, Chinese herbal medicine, clinical trials
- **Gary Deng**, MD, PhD – integrative med, acupuncture, Chinese med, clinical trials
- **Dawn Hershman**, MD, MS – breast medical oncology, natural products, epidemiology, clinical trials
- **Matthew Mumber**, MD – radiation oncology, mind-body interventions
- **Jane Perlmutter** – patient advocacy
- **Dugald Seely**, ND, MS – naturopathic med, research methods, systematic reviews, clinical trials
- **Ananda Sen**, PhD - biostatistics
- **Suzanna Zick**, ND, MPH – naturopathic med, natural products, acupressure, epidemiology, clinical trials

# Conflicts of Interest

- Financial conflicts of interest, including research support, were reviewed for all authors
- No financial conflicts of interest to disclose
- We noted that some authors have conducted/authored some of the studies included in the review

# Interventions of interest

- Natural products (e.g., botanicals, vitamins, minerals)
- Mind-body practices
  - Meditation
  - Yoga
  - Hypnosis
  - Imagery/Relaxation
  - Creative Therapies
  - Stress Management
  - Tai Chi/Qigong
- Acupuncture, acupressure, electroacupuncture
- Massage therapy
- Whole systems

Due to previous excellent reviews by *American Cancer Society*, *American Institute for Cancer Research*, and *American College of Sports Medicine*, decision not to include the following:

- Diet
- Physical activity
- Energy balance

# Clinically relevant outcomes of interest

- Fatigue
- Gastrointestinal
- Gynecological
- Hematological
- Lymphedema
- Neurological
- Neuromuscular
- Pain
- Psychological
- Quality of life
- Renal
- Skin
- Sleep
- Vasomotor symptoms

Note: Immune parameters were not included

# Search criteria

9 Databases: EMBASE, MEDLINE, PubMed, CINAHL, PsychINFO, Web of Science, SCOPUS, AMED, Acutrial

- Randomized controlled trial, AND
- Published January 1, 1990 - December 31, 2013, AND
- Breast cancer, AND
- Breast cancer treatment, AND
- Side effects/toxicities, AND
- Complementary/integrative therapies

# Inclusion criteria

1. Randomized controlled trial
2. Available in English
3. Included  $\geq 50\%$  breast cancer patients and/or reported results separately for breast cancer patients
4. Used an integrative modality as an intervention during standard treatment with surgery, chemotherapy, radiation therapy, and/or hormonal therapy, or addressed long-term side effects resulting from diagnosis and/or treatment
5. Had an outcome of interest

Other systematic reviews and meta-analyses were excluded.

# Search results

- 4,900 unique articles
- Article titles and abstracts were initially screened by at least 2 reviewers for inclusion for full review
- Full-text of articles that met criteria were assembled in online database accessible to the working group (Mendeley)
- Second round of screening consisted of a full-text scan to further remove articles that did not meet the inclusion criteria
- 203 articles met the criteria for final inclusion

# Quality scoring system

Scoring system	Question	Score
Jadad	1. Was the study described as randomized?	1=Yes, 0=No
	2. Was the method of randomization described in detail and appropriate?	1=Yes; 0=Not described in detail; 1=Described but not appropriate
	3. Was the study described as double-blinded?	1=Yes; 0=No
	4. Was the method of double-blinding described appropriate to maintain a double-blinding	If Q3=1 and double-blinding as described is appropriate, then Q4=1; If Q3=1 and double-blinding is not described, then Q4=0; If Q3=1 and double-blinding is inappropriate, then Q4=-1; If Q3=0, then Q4=0
	5. Was there a description of dropouts /withdrawals?	1=Yes/NA; 0=No
Modified Scale	1. Was there a description of dropouts /withdrawals?	1=Yes/NA; 0=No
	2. Was the method of randomization specified?	1=Yes; 0=No
	3. Was the eligibility criterion clearly laid out?	1=Yes; 0=No
	4. Is the Patient Blind to Study Arm?	1=Yes/N/A; 0.5=Don't Know; 0=No
	5. Is the Provider and/or Assessor Blinded to Study Arm?	1=Yes/N/A; 0.5=Don't Know; 0=No
	6. Is the sequence of study arm allocation concealed to the treatment assigner?	1=Yes/N/A; 0.5=Don't Know; 0=No
	7. Was there an objective strategy followed for treating missing data?	1=Yes; 0=No
	8. Was the study adequately powered for the primary outcomes?	1=Yes; 0.5=Don't Know; 0=No
	9. Point estimates and associated variability estimates (CI) presented for the primary outcome measures?	1=Yes; 0=No

Jadad *Control Clin Trials* 1996  
Verhagen *J Clin Epidemiol* 1998

# USPSTF grades

Grade	Definition	Suggestions for Practice
A	Recommends the modality. There is high certainty that the net benefit is substantial.	Offer/provide this modality.
B	Recommends the modality. There is high certainty that the net benefit is moderate or there is moderate certainty that the net benefit is moderate to substantial.	Offer/provide this modality.
C	Recommends selectively offering or providing this service to individual patients based on professional judgment and patient preferences. There is at least moderate certainty that the net benefit is small.	Offer/provide this modality for selected patients depending on individual circumstances.
D	Recommends against the service. There is moderate or high certainty that the modality has no net benefit.	Discourage the use of this modality.
H	Recommends against the service. There is moderate or high certainty that the harms outweigh the benefits.	Discourage the use of this modality.
I statement	Concludes that the current evidence is insufficient to assess the balance of benefits and harms of the service. Evidence is lacking, of poor quality, or conflicting, and the balance of benefits and harms cannot be determined.	Read the Clinical Considerations section of the USPSTF Recommendation Statement. If the service is offered, patients should understand the uncertainty about the balance of benefits and harms.

\*Adapted from U.S. Preventive Services Task Force

# Anxiety / stress reduction

## Grade B

- **Music therapy** is recommended for reducing anxiety during radiation therapy (RT) and chemotherapy (CT) sessions.
- **Meditation** is recommended for reducing anxiety in BC patients and those undergoing RT.
- **Stress management** is recommended for reducing anxiety during treatment, but longer group programs are likely better than self-administered home programs or shorter programs.
- **Yoga** is recommended for reducing anxiety in BC patients undergoing RT +/- CT and suggested for fatigued patients.

## Grade C

- **Acupuncture** can be considered for reducing anxiety in fatigued BC patients.
- **Massage** can be considered for short-term reduction of anxiety in BC patients.
- **Relaxation** can be considered for treating anxiety during treatment.

# Depression / mood

## Grade A

- **Meditation**, particularly MBSR, is recommended for treating mood disturbance and depressive symptoms in BC patients undergoing RT.
- **Relaxation** is recommended for improving mood and depressive symptoms when added to SC.
- **Yoga** is recommended for improving mood in women undergoing RT +/- CT and for fatigued BC patients in addition to SC.

## Grade B

- **Massage** is recommended for improving mood disturbance in post-treatment BC patients.
- **Music therapy** is recommended for improving mood in newly diagnosed BC patients.

## Grade C

- **Acupuncture** can be considered for improving mood in postmenopausal women experiencing hot flashes or fatigue.
- **Healing touch** can be considered for improving mood in BC patients undergoing CT.
- **Stress management** interventions with or without exercise can be considered for improving mood in BC patients.

# Fatigue

## Grade B

- **Energy Conservation Counseling** is recommended for the treatment of fatigue.

## Grade C

- **American Ginseng** is recommended as an herbal approach for the treatment of fatigue in BC patients.
- **Acupuncture** can be considered for the treatment of fatigue after the completion of cancer treatments.
- Modified **qigong** can be considered for the treatment of fatigue in BC patients.

## Grade D

- **Acetyl-L-carnitine** is not recommended for the treatment of fatigue due to lack of effect.
- **Guarana** is not recommended as an herbal for the treatment of fatigue due to lack of effect.

# Sleep

## Grade C

- **Stress management** techniques can be considered for the treatment of sleep disruption.
- Gentle **yoga** can be considered for the treatment of sleep disruption.

# Quality of life & physical functioning

## Grade A

- **Meditation** is recommended for improving quality of life among BC patients.

## Grade C

- **Acupuncture** can be considered for improving quality of life among cancer patients.
- **Guided imagery** can be considered for improving quality of life among BC patients.
- **Mistletoe** can be considered for improving quality of life among BC patients.
- **Qigong** can be considered for improving quality of life in cancer patients.
- **Reflexology** can be considered for improving quality of life among BC patients.
- **Stress management** can be considered for improving quality of life among BC patients.
- **Yoga** can be considered for improving quality of life among BC patients.
- **Exercise/ awareness** can be considered for improving functioning among BC patients.

## Grade D

- **Energy conservation** is not recommended for improving functioning among BC cancer patients due to lack of effect.

# Chemotherapy induced nausea and vomiting (CINV)

## Grade B

- **Acupressure** can be considered for BC patients receiving CT as an addition to antiemetics to help control nausea and vomiting during CT.
- **Electroacupuncture** can be considered for BC patients as an addition to antiemetics to control vomiting during CT.

## Grade C

- **Ginger** can be considered for BC patients receiving CT, without concurrent RT as an addition to antiemetics for the control of acute nausea.
- **Progressive muscle relaxation** can be considered for BC patients receiving CT as an addition to antiemetics to help control nausea and vomiting during CT.

## Grade D

- **Glutamine** is not recommended for use by BC patients receiving CT for the treatment of CINV due to lack of effect

# Pain

## Grade C

- **Energy and Sleep Enhancement** can be considered for pain associated with CT among unemployed individuals.
- **Massage** and **healing touch** can be considered for pain associated with CT.
- **Music therapy** can be considered to relieve pain associated with surgery.
- A **physical training program** that includes a mind-body modality can be considered for relieving pain associated with surgery among BC patients.
- **Hypnosis** can be considered for relief of associated with surgery in BC patients.
- **Acupuncture** can be considered as a non-pharmacologic approach to the short-term treatment of aromatase inhibitor-associated musculoskeletal symptoms (AIMSS).
- **Electroacupuncture** can be considered as a non-pharmacologic approach to the short-term treatment of AIMSS.

# Neuropathy

## Grade H

- **Acetyl-L-carnitine** is not recommended for prevention of neuropathy in BC patients due to harm.

## Insufficient evidence

- Electroacupuncture, vitamin B, omega-3 fatty acid, vitamin E

# Lymphedema

## Grade C

- **Laser therapy** can be considered as a treatment for lymphedema in BC patients.
- **Manual lymphatic drainage (MLD)** and compression bandaging have been shown to be equivalent. MLD can be considered for treatment of lymphedema in BC patients who have sensitivity to bandaging.

# Hot flashes

## Grade C

- **Acupuncture** can be considered for decreasing the number of hot flashes in BC patients.
- **Electroacupuncture** can be considered for decreasing the number of hot flashes in BC patients.

## Grade D

- **Soy** is not recommended for the treatment of hot flashes in BC patients and patients due to lack of effect.

# Acute radiation skin reaction

## Grade D

- **Aloe vera** is not recommended as a standard therapy to prevent or treat acute radiation skin reaction due to lack of effect.
- **Hyaluronic acid cream** is not recommended as a standard therapy to prevent or treat acute radiation skin reaction due to lack of effect.

# Strengths, Limitations and Caveats

- Up to date summary of RCTs with defined grading system
- Excluded older literature, meta-analyses and reviews
- Excluded trials that had a minority of breast cancer patients
- May have missed some trials using different keywords, not associated with cancer therapy
- Not all modalities (e.g., spirituality) were included
- Future trials need to standardize therapies, defined symptoms/eligibility, outcome measures, toxicity assessments
- Use of guidelines requires judgment, shared decision-making, risk/benefit analysis depending on situation (e.g., curability), follow-up/surveillance and adjustments

# Conclusions

- Clinical practice guidelines provide an aid to making complex clinical decisions
- Improve the ability for patients and clinicians to make healthcare decisions
- SIO aims to be the leader in developing trustworthy guidelines focused on integrative oncology

# Many thanks

## Research Assistants

### ***Columbia University***

Chip Bowman  
Melissa Dupont-Reyes  
Lindsay Greenawalt  
Jennifer Mongiovi  
Misa Nuccio  
Wendy Yu

### ***Canadian College of Naturopathic Medicine***

Heidi Fritz  
Amita Sachdev  
Cheryl Karthaus

### ***Ottawa Integrative Center Center***

Laura Weeks

### ***University of British Columbia***

Erin Waters

### ***University of California, San Francisco***

Caylie See

### ***University of Calgary***

Jillian Johnson  
Rie Tamagawa  
Jennifer White

### ***University of Michigan***

Kevin Shrestha  
Tofa Khabir

## Internal reviewers

SIO Board of Trustees  
Donald Abrams  
Lorenzo Cohen  
Gustav J. Dobos  
Erika Erickson  
Omer Kucuk  
Jun Mao  
Gregory Plotnikoff

## External reviewers

Gabriel N. Hortobagyi  
Anna Wu  
Musa Mayer  
Eun-Sil Shelley Hwang

## SIO Executive Committee

## JNCI

Meredith Abel  
Jan Martin